Idogen reports positive results for follow-up products in collaboration with the University of Oxford and strengthens the portfolio

Idogen AB (”Idogen”) reports positive results from the scientific collaboration with the University of Oxford. The study shows that treatment with two of the follow-up product molecules, for which the company has filed for patent protection, significantly reduces clinical symptoms in a model of rheumatoid arthritis. The results strengthen the Idogen’s possibilities for future licensing agreements of its technology for several indications.  

In June 2016, Idogen initiated a collaboration with Richard Williams’ research group at the Kennedy Institute of Rheumatology, University of Oxford. Richard Williams had previously carried out a successful study that showed a prolonged beneficial effect of Zebularine-treatment in a model of rheumatoid arthritis. The same study model has now been used to examine the treatment effect of potential follow-up molecules.

The study shows that two of the candidate drugs significantly reduce the clinical symptoms of rheumatoid arthritis. The treatment effect also persists for a period of time after cessation of treatment. In addition, follow-up test tube experiments indicate that these molecules, like Zebularine, support the tolerogenic loop that is important for a long-lasting effect, which further strengthens the results.

”The study shows that two of the follow-up molecules to Zebularine we have tested so far have a good treatment effect in a model of rheumatoid arthritis, which is very pleasing. This study confirms that we have interesting alternative candidates for new indications. The results strengthen the company’s platform and create important opportunities in the future to out-license projects in several indications” , CEO Lars Hedbys commented .

For additional information, please contact:

Lars Hedbys, CEO

Tel: +46 (0)46-275 63 30

E-mail: lars.hedbys@idogen.com

This is an English version of an original Swedish press release communicated by Idogen AB. In case of interpretation issues or possible differences between the different versions, the Swedish version shall apply . This constitutes information that Idogen AB is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on the 19th of September 2016.

For additional information, please contact:

Lars Hedbys, CEO

Tel: +46 - 46 - 275 63 30

E-mail: lars.hedbys@idogen.com

Idogen develops tolerogenic vaccines which re-program the immune system. The term "tolerogenic" refers to that the immune system will tolerate the selected molecule after treatment. It represents a new treatment method for autoimmune diseases, organ rejection after transplantation and patients without treatment after developing antibodies against standard treatment. The first indication for the therapy will be patients with the bleeding disorder hemophilia A who have developed an immunological reaction against their necessary factor VIII replacement.
The treatment method comprises cells from the patient's blood being reprogrammed to dendritic cells with the capacity to specifically counteract the adverse immune reaction. The company's technology platform has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently cannot be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation.
Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University. For more information, visit www.idogen.com

About Us

Idogen develops tolerogenic vaccines which re-program the immune system. The company's technology has the potential to develop long-acting treatment of anti-drug antibodies as well as autoimmune diseases that currently can not be cured. In addition, Idogen has the potential to change the transplantation market by reducing the need for immunosuppressive therapy after transplantation. Idogen was founded in 2008 based on a fundamental immunological discovery at Lund University.

Subscribe

Documents & Links

Quotes

The study shows that two of the follow-up molecules to Zebularine we have tested so far have a good treatment effect in a model of rheumatoid arthritis, which is very pleasing. This study confirms that we have interesting alternative candidates for new indications. The results strengthen the company’s platform and create important opportunities in the future to out-license projects in several indications
CEO Lars Hedbys